

RESEARCH REPORT



ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKETS, STRATEGIES AND TRENDS BY PATHOGEN AND TECHNOLOGY, WITH EXECUTIVE GUIDES AND CUSTOMIZATION. 2022 TO 2026



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the X-Ray market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Market Guides.....	17
1.1	Antimicrobial Resistance - Strategic Situation Analysis	18
1.2	Guide for Executives and Business Development Staff.....	20
1.3	Guide for Management Consultants and Investment Advisors.....	22
2	Introduction and Market Definition	23
2.1	The Threat and Opportunity of Antimicrobial Resistance	24
2.2	Defining the Opportunity.....	27
2.2.1	Revenue Market Size	27
2.3	Methods and Sources.....	29
2.3.1	Methodology	29
2.3.2	Sources	29
2.3.3	Authors.....	30
2.4	U.S. Antibiotic Markets - Perspective.....	31
2.4.1	U.S. Outpatient Use of Antibiotics.....	32
2.4.2	U.S. Pharmaceutical Spending.....	35
3	Overview of a Dynamic Market	37
3.1	Market Players – Roles & Impacts.....	38
3.1.1	Drug manufacturers - Larger/pharmaceutical	39
3.1.2	Drug manufacturers - Generic	40

3.1.3	Contract Research and Manufacturing	41
3.1.4	In Vitro Diagnostics Industry	42
3.1.5	Drug Marketing Companies	43
3.1.6	Biotechnology Companies	43
3.1.7	Regulatory Bodies	44
3.2	Understanding Antimicrobial Resistance	46
3.2.1	What is Antimicrobial Resistance (AMR)	46
3.2.2	Bacteria and Other Microbes.....	47
3.2.3	The History of Antibiotics.....	54
3.2.4	The Role of Animal Husbandry.....	59
3.2.5	The Implications of Horizontal Transfer.....	60
3.2.6	The Threat of AMR	62
3.3	The Changing Road to New Antibiotics & Technologies.....	64
3.4	The Key Role of Diagnostics in AMR.....	67
4	The Market Opportunity of AMR	68
4.1	The Key Large Market Opportunities in AMR	69
4.1.1	Streptococcus Pneumoniae (DRSP)	70
4.1.2	Campylobacter (DRC)	73
4.1.3	Clostridium Difficile (CD)	76
4.1.4	Staphylococcus aureus (MRSA)	79
4.1.5	Neisseria gonorrhoeae (DRNG)	83
4.1.6	Salmonella (DRNTS)	87

4.2	Diagnostic Technology Development Opportunities.....	90
4.2.1	What's Wrong with Microbiology	92
4.2.2	The Features Battleground of Infectious Disease Diagnostics.....	92
4.2.3	Multiplex vs. POC/Rapid.....	92
4.2.4	The Miracle of Genetics	93
4.2.5	From Multiple Pathogens to All Pathogens – The Next Next Generation	95
4.2.6	Gene Sequence Diagnostics WITHOUT the Sequencing.....	95
4.2.7	Markers of Resistance.....	96
4.2.8	What Happens to the Microbiology Lab?	96
5	Antibiotic Resistance Diagnostics Recent Developments	97
5.1	Antibiotic Resistance Recent Developments	98
5.1.1	Importance of These Developments.....	98
5.1.2	How to Use This Section	98
5.2	T2 Biosystems Exercises BARDA Option	98
5.3	OpGen to Ramp up Use of Acuitas AMR Gene Panel.....	100
5.4	BD Partners With Pfizer, Wellcome to Study AMR Dx.....	104
5.5	Sepsis Test Developers Accelerate Plans	105
5.6	OpGen Receives FDA Clearance for AMR Panel.....	111
5.7	Visby Medical - Rapid Uptake of Handheld PCR Test for STIs.....	112
5.8	MicroGenDx, OrthoKey Clinic and OrthoKey Surgery.....	114
5.9	BioMérieux Receives CE Mark for Vitek Clinical Microbiology System.....	115

5.10	Hologic to Acquire Mobidiag	116
5.11	Campylobacter strains exchange genes	117
5.12	Disinfection spreads antimicrobial resistance	120
5.13	Molzym, Fraunhofer Developing Rapid Sepsis Dx	121
5.14	Illumina, IDbyDNA Build NGS-Based Respiratory Panel	127
5.15	Accelerate Diagnostics Expands AMR Testing	133
5.16	Rapid diagnostics linked to optimal antibiotics	134
5.17	Visby Medical Wins AMR Diagnostic Competition	135
5.18	DNAe Technology SARS-CoV-2 Sequences.....	136
5.19	Infections with foodborne bacteria becoming harder to treat...	138
5.20	Dust is sharing antibiotic resistance genes.....	141
5.21	Report predicts drug resistance likely to kill 400,000	142
5.22	New method to test for infection resistance.	146
5.23	Qiagen launches AMR database	148
5.24	Antibiotic resistance test for gonorrhea gets FDA breakthrough	150
5.25	Qiagen, Ares Genetics Ink Licensing Pact for AMR Bioinformatics 151	
6	Key AMR Diagnostics Companies	153
6.1	1928 Diagnostics	154
6.2	Abacus Diagnostica	155
6.3	Abbott Laboratories.....	156
6.4	Accelerate Diagnostics	158

6.5	ADT Biotech.....	159
6.6	Beckman Coulter Diagnostics	160
6.7	Becton, Dickinson and Company.....	161
6.8	Binx Health.....	163
6.9	bioMérieux Diagnostics.....	165
6.10	Bio-Rad Laboratories, Inc.	168
6.11	Cepheid (Danaher)	171
6.12	Curetis N.V. / Curetis GmbH.....	173
6.13	Day Zero Diagnostics.	175
6.14	Enzo Biochem.....	176
6.15	Eurofins Scientific	178
6.16	Fusion Genomics.	181
6.17	GeneFluidics.....	183
6.18	Great Basin Corporation	184
6.19	Hologic.....	186
6.20	Hutman Diagnostics	189
6.21	Inflammatix.....	190
6.22	Linear Diagnostics.....	192
6.23	Lumos Diagnostics	193
6.24	Millipore Sigma.....	194
6.25	OpGen.....	195
6.26	Ortho Clinical Diagnostics	197

6.27	Perkin Elmer	199
6.28	Qiagen.....	201
6.29	Roche Molecular Diagnostics.....	204
6.30	SeLux Diagnostics	206
6.31	Sense Biodetection	208
6.32	Siemens Healthineers	210
6.33	Sysmex.....	213
6.34	Thermo Fisher Scientific Inc.	216
6.35	Visby Medical.....	219
7	The Global Market for Antimicrobial Resistance Diagnostics	221
7.1	Global Market Overview by Country.....	222
7.1.1	Table – Global Market by Country.....	222
7.1.2	Chart - Global Market by Country	223
7.2	Global Market by Technology - Overview.....	224
7.2.1	Table – Global Market by Pathogen	224
7.2.2	Chart – Global Market by Pathogen – Base/End Year Comparison	225
7.2.3	Chart – Global Market by Pathogen – Base Year.....	226
7.2.4	Chart – Global Market by Pathogen – End Year	227
7.2.5	Chart – Global Market by Pathogen – Share by Year	228
7.2.6	Chart – Global Market by Pathogen – Segment Growth	229
7.3	Global Market by Technology - Overview.....	230

7.3.1	Table – Global Market by Technology	230
7.3.2	Chart – Global Market by Technology – Base/End Year Comparison	231
7.3.3	Chart – Global Market by Technology – Base Year	232
7.3.4	Chart – Global Market by Technology – End Year	233
7.3.5	Chart – Global Market by Technology – Share by Year	234
7.3.6	Chart – Global Market by Technology – Segment Growth	235
8	Global Antibiotic Resistance Diagnostic Markets – By Pathogen	236
8.1	Drug Resistant Streptococcus Pneumoniae - DRSP	237
8.1.1	Table DRSP – by Country	237
8.1.2	Chart - DRSP Growth	238
8.2	Drug Resistant Campylobacter - DRC	239
8.2.1	Table DRC – by Country	239
8.2.2	Chart - DRC Growth	240
8.3	Clostridium Difficile - CD	241
8.3.1	Table CD – by Country	241
8.3.2	Chart - CD Growth	242
8.4	Methicillin Resistant Staphylococcus Aureus - MRSA	243
8.4.1	Table MRSA – by Country	243
8.4.2	Chart – MRSA Growth	244
8.5	Drug Resistant Neisseria Gonorrhoeae - DRNG	245
8.5.1	Table DRNG – by Country	245

8.5.2	Chart – DRNG Growth	246
8.6	Drug Resistant Salmonella - DRNTS.....	247
8.6.1	Table DRNTS – by Country	247
8.6.2	Chart – DRNTS Growth	248
9	Global Antibiotic Resistance Diagnostic Markets – by Technology	249
9.1	Microbiology Culture	250
9.1.1	Table Culture – by Country	250
9.1.2	Chart – Culture Growth	251
9.2	Immunoassay	252
9.2.1	Table Immunoassay – by Country	252
9.2.2	Chart - Immunoassay Growth	253
9.3	PCR	254
9.3.1	Table PCR – by Country.....	254
9.3.2	Chart - PCR Growth	255
9.4	NGS.....	256
9.4.1	Table NGS – by Country	256
9.4.2	Chart - NGS Growth	257
9.5	Mass Spectrometry - MS	258
9.5.1	Table MS – by Country	258
9.5.2	Chart - MS Growth.....	259
9.6	Rapid and Point of Care – Rapid/POC	260
9.6.1	Table Rapid/POC – by Country	260

9.6.2 Chart - Rapid/POC Growth261

10 Vision of the Future of AMR Diagnostics262

11 Appendices.....263

11.1 United States Medicare System: 2022 Clinical Laboratory Fees
Schedule.....263

Table of Tables

Table 1 USA - Outpatient Use of Antibiotics by Class	33
Table 2 USA - Outpatient Use of Antibiotics Top 5	34
Table 3 Market Players by Type.....	38
Table 4 Known Human Pathogenic Diseases.....	50
Table 5 The Key Market Opportunities	69
Table 6 - Market Potential DRSP Diagnostic	72
Table 7 - Market Potential DRC Diagnostic	75
Table 8 - Market Potential CD Diagnostic	77
Table 9 - Market Potential CD Diagnostic	81
Table 10 Market Potential DRNG Diagnostic.....	85
Table 11 Market Potential DRNTS Diagnostic	88
Table 12 – Key AMR Diagnostics Issues.....	90
Table 13 - Global Market by Region.....	222
Table 14 Global Market by Pathogen.....	224
Table 15 Global Market by Technology.....	230
Table 16 DRSP by Country.....	237
Table 17 DRC by Country.....	239
Table 18 CD by Country	241

Table 19 MRSA by Country243

Table 20 DRNG by Country.....245

Table 21 DRNTS by Country.....247

Table 22 Culture by Country.....250

Table 23 Immunoassay by Country252

Table 24 PCR by Country254

Table 25 NGS by Country256

Table 26 MS by Country258

Table 27 Rapid/POC by Country260

Table 28 2022 Clinical Lab Fee Schedule263

Table of Figures

Figure 1 Pharmaceutical Spending History by Country	35
Figure 2 AMR and Antibiotic Introduction	58
Figure 3 The Death Toll of AMR.....	62
Figure 4 Global Market Share Chart.....	223
Figure 5 Global Market by Pathogen – Base vs. End Year	225
Figure 6 Global Market by Pathogen Base Year	226
Figure 7 Global Market by Pathogen End Year.....	227
Figure 8 Pathogen Share by Year.....	228
Figure 9 Pathogen Segment Growth	229
Figure 10 Technology - Base vs. End Year Segment Shift.....	231
Figure 11 Technology Market Base Year.....	232
Figure 12 Technology Market End Year	233
Figure 13 Technology Share by Year.....	234
Figure 14 Technology Segment Growth	235
Figure 15 DRSP Growth	238
Figure 16 DRC Diagnostics Growth.....	240
Figure 17 CD Growth	242
Figure 18 MRSA Growth.....	244
Figure 19 DRNG Growth	246

Figure 20 DRNTS Growth 248

Figure 21 Culture Growth 251

Figure 22 Immunoassay Growth..... 253

Figure 23 PCR Growth..... 255

Figure 24 NGS Growth 257

Figure 25 MS Growth..... 259

Figure 26 Rapid/POC Growth..... 261